RxDoctor Payments Data

Katherine Lowary

Psychiatric/Mental Health · Burlington, IANPI 1336853415

Payments from drug & device makers

$1,290in general payments, 2019–2025

Across 67 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$211
  • Teva Pharmaceuticals USA, Inc.$175
  • Otsuka America Pharmaceutical, Inc.$164
  • Lundbeck LLC$162
  • Alkermes, Inc.$159
  • Johnson & Johnson$117
  • plus $302 from 6 others

What the payments were for

  • Food & beverage$1,24196%
  • Education$494%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,290 in reported general payments places this provider in the 60th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$35,329
Medicare patients
45
Services billed
722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole53$52,375
Abilify MaintenaAripiprazole17$46,288
Invega SustennaPaliperidone Palmitate12$37,435
FanaptIloperidone25$35,576
VraylarCariprazine Hcl22$29,746
XanaxAlprazolam12$9,800
Aripiprazole124$8,653
TrintellixVortioxetine Hydrobromide14$6,900
Adderall XrDextroamphetamine/Amphetamine12$5,163
Olanzapine46$5,133
Divalproex Sodium ErDivalproex Sodium105$4,058
Clozapine66$3,642
Fluphenazine Hcl47$3,061
Atomoxetine Hcl22$2,768
Duloxetine Hcl92$2,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$164$98,66370 claims
Johnson & JohnsonInvega Sustenna$117$37,43512 claims
Vanda Pharmaceuticals Inc.Fanapt$74$35,57625 claims
AbbVieVraylar$16$29,74622 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$77$6,90014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Burlington

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →